DNLI vs PSA · $2.11B cap vs rev $4.82B
Denali Therapeutics Inc (DNLI) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported DNLI revenue for 2024-12-31 was $0. Net income was -$422.8M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. DNLI currently screens at market cap $2.11B.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
DNLI currently screens at market cap $2.11B. PSA currently screens at market cap $0.
Not investment advice. Open the DNLI and PSA stock pages for the full models.
Not investment advice.